Kristyn Aalto | Chief Executive Officer
Orlance, Inc.

Kristyn Aalto, Chief Executive Officer, Orlance, Inc.

Kristyn Aalto, Orlance CEO, founded Seattle-based Orlance, Inc. along with University of Washington faculty Deboral Fuller, PhD and James Mullins, PhD to develop pneumatically-delivered DNA and RNA vaccine and therapeutics that address multiple clinical and logistics needs within today’s rapidly evolving biotechnology landscape.  Ms. Aalto has 30 years of experience within the biotechnology, medical technology, and innovation development fields; her past roles have spanned Fortune 500, growth company, early start-up and research institution environments.  A serial biotech entrepreneur during the past 12 years, Ms. Aalto has led formative fundraising and preclinical programs, regulatory approvals, clinical program management, market launches, and ongoing commercial support.  A biomedical engineer by training and Marquette University alumnus, Ms. Aalto is currently based in Seattle, WA and Coeur d’Alene, ID.


Day 1 - November 28 @ 13:15

Start-up: MACH-1TM Epidermally Delivered Powdered Vaccine Platform

last published: 02/Jan/24 12:15 GMT

back to speakers